What injection can be given to a dog for ticks? - briefly
Fluralaner, marketed as Bravecto Injectable, is a veterinary‑approved subcutaneous injection that provides systemic protection against ticks for up to 12 weeks. It is given by a veterinarian in a single dose and covers all major tick species affecting dogs.
What injection can be given to a dog for ticks? - in detail
Injectable fluralaner (commercially known as Bravecto Injectable) is the primary parenteral option for canine tick control. The product is a sterile suspension administered subcutaneously, typically in the dorsal lumbar region. One dose delivers protection against a broad spectrum of tick species for up to 12 weeks, with simultaneous efficacy against fleas.
Dosage is calculated on body weight:
- 2 kg – 4.9 kg: 0.5 mL (50 mg fluralaner)
- 5 kg – 9.9 kg: 1.0 mL (100 mg)
- 10 kg – 19.9 kg: 2.0 mL (200 mg)
- 20 kg – 39.9 kg: 4.0 mL (400 mg)
- 40 kg – 79.9 kg: 8.0 mL (800 mg)
- ≥80 kg: 16.0 mL (1,600 mg)
The injection is given once every three months; re‑treatment may be scheduled earlier if the dog is at high risk of heavy tick exposure. The formulation is stable at room temperature, protected from light, and should be used within the manufacturer‑specified shelf life.
Safety data indicate a low incidence of adverse events. Most reported reactions are transient injection‑site discomfort or mild gastrointestinal upset. Contraindications include dogs younger than eight weeks, animals weighing less than two kilograms, and individuals with known hypersensitivity to fluralaner or any excipients. Caution is advised for pregnant or lactating dogs, and for those with compromised liver function.
Pharmacologically, fluralaner antagonizes γ‑aminobutyric‑acid‑gated chloride channels in arthropods, leading to rapid paralysis and death of attached ticks. The systemic mode of action eliminates the need for topical application, reduces the risk of environmental contamination, and provides consistent plasma concentrations regardless of grooming behavior.
Veterinarians should verify accurate weight measurement before administration, record the injection date, and advise owners to monitor for any post‑injection abnormalities. Proper storage, handling, and adherence to the dosing schedule ensure maximal efficacy and minimize the likelihood of tick‑borne disease transmission.